Shuichi Shirane
Overview
Explore the profile of Shuichi Shirane including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
291
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shirane S, Yasuda H, Uchimura A, Mori Y, Inano T, Tsutsui M, et al.
Case Rep Oncol
. 2025 Feb;
18(1):1-6.
PMID: 39980503
Introduction: Splenomegaly is frequently encountered in patients with myeloproliferative neoplasms. Splenomegaly is associated with an increased incidence of engraftment failure during allogeneic hematopoietic stem cell transplantation (allo-HSCT), and some centers...
2.
Edahiro Y, Shirane S, Takeda J, Yasuda H, Inano T, Tsutsui M, et al.
Int J Hematol
. 2024 Dec;
121(2):281-283.
PMID: 39641876
No abstract available.
3.
Furuya C, Hashimoto Y, Morishita S, Fukuda Y, Inano T, Ochiai T, et al.
Hematology
. 2024 Nov;
29(1):2427905.
PMID: 39545588
Objectives: Hemorrhagic events are a rare but potentially fatal complication in patients with polycythemia vera (PV). Methods: We analyzed the characteristics of hemorrhagic events in 267 patients with PV. Results:...
4.
Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera
Kirito K, Sugimoto Y, Gotoh A, Takenaka K, Ichii M, Inano T, et al.
Int J Hematol
. 2024 Oct;
120(6):675-683.
PMID: 39361233
Ropeginterferon alfa-2b (ropegIFN), a new-generation interferon-based agent, has been approved in Japan for patients with polycythemia vera (PV) who are ineligible for or respond inadequately to conventional treatment. However, long-term...
5.
Shirane S
Rinsho Ketsueki
. 2024 Sep;
65(8):790-797.
PMID: 39231710
Budd-Chiari syndrome (BCS) is a rare vascular disorder characterized by obstruction of hepatic venous outflow, culminating in elevated hepatic and portal venous pressure. BCS is associated with myeloproliferative neoplasms (MPN)...
6.
Furukawa Y, Ando J, Ishii M, Kinoshita S, Goto A, Tachibana K, et al.
Br J Haematol
. 2024 Jul;
205(4):1610-1614.
PMID: 39030904
No abstract available.
7.
Kaito S, Najima Y, Sadato D, Hirama C, Kishida Y, Nagata A, et al.
Bone Marrow Transplant
. 2024 May;
59(8):1169-1175.
PMID: 38783125
Disease recurrence remains the principal cause of treatment failure after allogeneic hematopoietic stem cell transplantation. Post-transplant maintenance therapy with azacitidine (AZA) is promising to prevent relapse but the outcomes are...
8.
Furuya C, Yasuda H, Hiki M, Shirane S, Yamana T, Uchimura A, et al.
Front Immunol
. 2024 Feb;
15:1287300.
PMID: 38333218
Persistent COVID-19 is a well recognized issue of concern in patients with hematological malignancies. Such patients are not only at risk of mortality due to the infection itself, but are...
9.
Uchimura A, Yasuda H, Onagi H, Inano T, Shirane S, Ishii M, et al.
Heliyon
. 2024 Feb;
10(2):e24801.
PMID: 38312561
Background: Acute graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with significant morbidity and mortality, and efficacy of currently available therapeutics are limited. Acute...
10.
Furuya C, Morishita S, Hashimoto Y, Inano T, Ochiai T, Shirane S, et al.
Br J Haematol
. 2023 Nov;
204(1):221-228.
PMID: 37920129
Risk-adapted therapy is recommended to prevent major clinical complications, such as thrombo-haemorrhagic events, in patients with essential thrombocythaemia (ET). In this study, we analysed the association between non-driver gene mutations...